Picture EBD Group BIO-Europe Spring 2020 Paris BEU2020 650x75

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5523 | Ordered by Deal: Collaboration or Financing (descending)
1 2 3 ... 54 55 56  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Zytoprotec–Baxter: investment, 201301 financing €2m from new investor Baxter Ventures 2013-01-29
Zürcher Kantonalbank–Bellevue: investment, 201409– acquisition 100% of Adamant Biomedical Investments AG from ZKB 2014-09-05
Zymeworks–Minapharm: GlymaxX technology, 201510– supply service cell line development for bispecific antibody production applying GlymaxX by ProBioGen 2015-10-14
Zweckverband Landeswasserversorgung–Danaher: mass spectrometer, 201012– supply AB Sciex TripleTOF 5600 to Waterworks Langenau + collab method developm 2010-12-08
Zivak Technologies–Tecan: automated liquid handling, 201310 supply Cavro Omni Robot for use with clinical Dx HPLC + LC-MSMS systems 2013-10-22
Zinsser Analytic–Kohlberg Kravis Roberts: investment, 201609 acquisition of ILS Gmbh + Zinsser Analytic GmbH from Mr+Ms Zinsser by Gardner Denver 2016-09-01
Zinc Ahead–Veeva Systems: investment, 201509 acquisition $130m in cash incl $10m deffered consideration over 3 years 2015-09-29
ZIM Plant Technology–Yara: investment, 201311–201401 acquisition by Yara
ZIM Plant Technology–High-Tech Gründerfonds: investment, 201204 investment by HTGF 2012-04-04
Ziarco–Novartis: investment, 201612 acquisition €na by Novartis ANNOUNCED 2016-12-16
Zespri–Metabolomic Discoveries: metabolomic services, 201601– supply service MS-based profiling of kiwi fruit using Flavour Profiler Technology 2016-01-18
Zernike–Bremen (govt): grant, 201008 investment €9.6m for opening up for development the estate for Jacobs Science Park JUST 2010-08-31
Zeltia–Scienion: DNA microarrays, 201211– collab expansion product integration to provide molecular microarray solutions Genomia SAU 2012-11-05
Zellkraftwerk–MHH: Switch-Antibodies technology, 201510– license ww excl to Zellkraftwerk GmbH from MHH 2015-10-20
Zellkraftwerk–Helmholtz: investment, 201510 Ascenion acquires equity position under license agreem with MHH for Switch-Antibodies technology 2015-10-20
Zellkraftwerk–Canopy Biosciences: investment, 201904 acquisition of Zellkraftwerk GmbH by Canopy Biosciences 2019-04-29
Zedira–Univ Marburg: structural biology, 201502 collab existent w group of Prof Gerhard Klebe 2015-02-03
Zedira–R-Biopharm: investment, 201206 existing investor is R-Biopharm AG 2012-06-22
Zedira–High-Tech Gründerfonds: investment, 200912 existent Zedira GmbH is active investment of HTGF 2009-12-28
Zedira–Germany (govt): grant, 201611– BMBF KMU-Innovativ funding €1.5m for 3y to support developm of ZED1227 in diabetic nephropathy 2016-11-30
Zedira–Germany (govt): grant, 201502– BMBF funding €1m to support further coagulation factor XIIIa inihibitor development 2015-02-03
Zedira–Cardiff Univ: drug discovery, 201509– collab research role of transglutaminase 6 in disease pathway of cerebellar ataxia 2015-09-22
Zavante Therapeutics–SEVERAL: investment, 201603 financing round Series A $45m with $35m from new investors + $10m conversion of convertible notes 2016-03-30
Zavante Therapeutics–Nabriva: investment, 201807 acquisition upfront 8.2m Nabriva ordinary shares (=19.9% shareholding) + $97.5m milestones 2018-07-24
Yumda–Chemie.DE: investment, 201704 acquisition of Yumda GmbH by Chemie.DE Information Service GmbH 2017-04-01
Yukin Therapeutics–SEVERAL: investment, 201906 financing round €3.3m co-led by Advent France Biotechnology + Medicxi 2019-06-04
Yuhan–Cevec: CAP technology, 201212– license to use CAP + CAP-T cell expression systems therapeutic protein developm + production 2012-12-20
YES Pharma Services–Auctus Capital: investment, 201410 acquisition of majority share by funds advised by Auctus Capital Partners AG 2014-10-22
Xtal Concepts–Hamburg (govt): investment, 201207 investment in Xtal Concepts GmbH by Innovationsstarter Fonds Hamburg 2012-07-16
Xradia–Carl Zeiss: investment, 201306–201307 acquisition of Xradia Inc renamed Carl Zeiss X-ray Microscopy Inc 2013-06-13
Xpand Biotechnology–Kuros: investment, 201612 merger acquisition of Xpand Biotechnology BV by Kuros Biosciences AG for up to 2.105m new Kuros shares 2016-12-19
Xiril–Sias: investment, 2012 acquisition of Xiril AG by Sias AG 2012-01-01
Xigen–Instinctif Partners: public relations, 201701 service existent by Instinctif Partners 2017-01-05
Xenikos–MC Services: public relations, 201605 service existent for Xenikos BV by MC Services AG Düsseldorf 2016-05-24
Xencor–Selexis: cell line development, 201611– supply service strategic agreem for SUREtechnology for developm of multi-specific antibodies 2016-11-03
Xencor–Selexis: cell line development, 2011– supply service agreem for SUREtechnology for developm of multi-specific antibodies 2011-01-01
Xencor–JSR Corp: cell line development, 201802– four commercial licenses to use Selexis’ SUREtechnology for developm of bispecific antibodies 2018-02-26
Xencor–Boehringer: rec protein production, 201202– service + collab developm + manufacture + supply of mABs using Xtend technology for Xencor 2012-02-21
Xeltis–VI Partners: investment, 201412 financing round Series B totalling €27m incl co-investor VI Partners 2014-12-02
Xeltis–SEVERAL: investment, 201711 financing round Series C €45m led by a global strategic investor + incl Ysios Capital + LSP + Kurma Partners et al 2017-11-15
Xeltis–SEVERAL: investment, 201512 financing round Series B extension €3m bringing total Series B to €30m 2015-12-17
Xeltis–SEVERAL: investment, 201412 financing round Series B €27m co-led by LSP + Kurma Partners plus VI Partners + current investors 2014-12-02
Xeltis–Life Sciences Partners: investment, 201412 financing round Series B totalling €27m co-led by LSP + Kurma Partners 2014-12-02
Xeltis–Kurma: investment, 201412 financing round Series B totalling €27m co-led by LSP + Kurma Partners 2014-12-02
X4 Pharmaceuticals–Arsanis: investment, 201811– reverse merger with former X4 owners to hold 70% + Arsanis to be renamed X4 ANNOUNCED 2018-11-27
X-Zyme–Johnson Matthey: investment, 201007 acquisition 2010-07-05
WuXi PharmaTech–Ally Bridge Group: investment, 201702 existent investment of ABG 2017-02-23
Wise (IT)–SEVERAL: investment, 201705 financing round Series B €6.5m led by Prinicpia SGR + incl Atlante Ventures + HTGF + F3F + Antares 2017-05-25
Wiley–Medical Univ Innsbruck: MSforID Library, 201106 collab Wiley publishes MSforID as Wiley Registry of Tanden Mass Spectral Data 2011-06-14
Wiley–GeneBio: SmileMS software, 201105– collab ww non-excl co-distribution of SmileMS with LC-MS/MS libraries 2011-05-30
Wilex–Yorkville Group: investment, 201003– standby equity line up to $20m new shares to be purchased within 3y by YA Global Master SPV on request 2010-03-23
Wilex–UCB: credit, 201012–201405 subordinated loan up to €2.5m interest rate 6% annual from UCB Pharma SA REPAYMENT WAIVED 5/14 2010-12-17
Wilex–TVM: investment, 200907 existent current public portfolio company of TVM 2009-07-01
Wilex–SEVERAL: investment, 201704– capital increase €4.99m with rights issue to existing shareholders incl dievini Hopp 2017-04-24
Wilex–SEVERAL: investment, 201604 capital increase €4.13m with 2.25m new shares at €1.84/share whereof >50% to Dievini Hopp 2016-04-25
Wilex–SEVERAL: investment, 201512 investment €815k w 443,124 new shares at €1.84/share to existent shareholders 2015-12-09
Wilex–SEVERAL: investment, 201504 capital increase €4.16m with 1.5m new shares €2.8/share 2015-04-07
Wilex–SEVERAL: investment, 201201–201202 capital increase €9.93m with 3.2m new authorised shares €3.1/share 2012-01-09
Wilex–SEVERAL: investment, 201007–201008 private placement €10m 2.46m new shares €4.1/share to existing investors incl Hopp + UCB 2010-07-19
Wilex–Nuclea Biotechnologies: investment, 201309 acquisition 100% of Wilex Inc by Nuclea w repayment $2.5m interfirm loan + $2.5m services + royalties 2013-09-06
Wilex–Hopp Group: investment, 201702– financing commitment of up to €10m by Dievini Hopp [not announced whether credit or investment] 2017-02-06
Wilex–Hopp Group: investment, 201512 investment €1.712m w 930,560 new shares at €1.84/share dievini Hopp BioTech holding 2015-12-09
Wilex–Hopp Group: credit, 201012– subordinated loan up to €7.5m interest rate 6% annual from Dievini Hopp BioTech Holding GmbH & Co KG 2010-12-17
Wilex–Germany (govt): grant, 201202– BMBF funding of up to €2.6m for developm of WX-037 within m4 Cluster Initiative 2012-02-06
Westburg–Medicyte: cell technology, 201302– distribution of upcyte + vericyte technology + products in Benelux by Westburg BV 2013-02-13
Westburg–Analytik Jena: investment, 201107 acquisition 20% stake in Westburg BV for €150k 2011-07-18
Werum–Körber: investment, 201402– acquisition of newly formed Werum IT Solutions AG by Körber Medipak 2014-02-10
Werfen–Protagen: biomarker, 201608– license semi-excl for use of BICD2 biomarker for diagnosis of systemic sclerosis to Inova Diagnostics 2016-08-11
Wellington Partners–UTIMCO: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor UTIMCO 2019-07-31
Wellington Partners–Univ Texas: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor Univ Texas/Texas A&M Investment Company 2019-07-31
Wellington Partners–Talanx: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor Talanx 2019-07-31
Wellington Partners–SEVERAL: investment, 201907 final closing €210m WPLS-V fund incl investors KfW Capital + Talanx + UTIMCO + Univ Texas + EIB 2019-07-31
Wellington Partners–MC Services: public relations, 202001 service existent by MC Services 2020-01-08
Wellington Partners–Germany (govt): investment, 201907 final closing totalling €210m WPLS-V fund incl new investor KfW Capital 2019-07-31
Wellington Partners–EU (govt): investment, 201907 final closing totalling €210m WPLS-V fund incl exisiting investor EIB/EIF 2019-07-31
Wellington Partners–Consilium: public relations, 201907 service existent by CSC 2019-07-31
Wellington Partners–CMS: legal services, 201811 supply service legal advice by CMS for both lead investors HBM + Wellington of Adrenomed Series D 2018-11-01
Weizmann Institute–XL-protein: PASylation technology, 201410– Yeda acquires ww excl marketing + outlicensing rights to PAS-YNSa8 dev by XL + Weizmann 2014-10-21
Weizmann Institute–Thermo Fisher: mass spectrometer, –201006– supply existent LTQ-XL-Orbitrap at Biological Mass Spec Facility 2010-06-18
Weizmann Institute–Bruker: MRI system, 201710 supply Biospec 15.2 Tesla USR preclinical UHF MRI system 2017-10-18
WeissBioTech–BRAIN: investment, 201411 acquisition €na of majority shareholding in WeissBioTech GmbH by BRAIN AG 2014-11-27
WBM Health Science–Medicyte: cell technology, 201306– collab promotion of Medicyte products + services in India by WBM 2013-06-25
Waters–Tecan: liquid handling technology, 201201– supply €na OEM Freedom EVO platform for Waters clinical lab assays with ACQUITY TQD LS/MS/MS 2012-01-17
Waters–Biocrates: AbsoluteIDQ Kits, 201205– collab Waters Xevo TQ MS editions of established AbsoluteIDQ p180 + p150 kits 2012-05-14
Waters–Andrew Alliance: automated liquid handling technology, 201902–collab new solutions for LC-MS research 2019-02-06
Waters–Andrew Alliance: automated liquid handling technology, 201706– collab co-marketing semi-automated sample prep solution 2017-06-01
Warp Drive Bio–Revolution Medicines: investment, 201810 acquisition of Warp Drive Bio by Revolution Medicines 2018-10-16
Wagner Analysen Technik–Orexo: investment, 201107 acquisition €1.4m + milestones by Kibion AB 2011-07-14
Wageningen Univ–Thermo Fisher: mass spectrometer, 201511 supply existent use of Q Exactive GC system by Marc Tienstra at RIKILT 2015-11-03
Wageningen Univ–Thermo Fisher: mass spectrometer, 201503 supply existent Hans Mol RIKILT Wageningen UR early access user of Q Exactive Focus 2015-03-09
VTU–Univ Oxford: recombinant protein production, 201109 collab existent Univ Oxford is partner of VTU Technology GmbH 2011-09-13
VTU–TU Graz: recombinant protein production, 201109 collab existent Graz Univ of Technology is partner of VTU Technology GmbH 2011-09-13
VTU–KonValue: investment, 201810 acquisition of VTU Technology by KonValue Group from VTU Holding GmbH + renaming as Validogen GmbH 2018-10-22
VTU–ACIB: recombinant protein production, 201109 collab existent ACIB is partner of VTU Technology GmbH 2011-09-13
Volution Immuno Pharmaceuticals–Celsus Therapeutics: investment, 201508– reverse merger acqu of VIP by Celsus to be renamed Akari Therapeutics 2015-07-13
Vivoryon–Trophic Communications: public relations, 201910 service existent by Trophic
Vivoryon–SEVERAL: investment, 201910– public rights offering €30m–€70m incl Claus Chrisitansen + Den Danske Forskningsfond + T&W Holding + MorphoSys 2019-10-08
Vivoryon–MorphoSys: investment, 201910– public rights offering totalling €30m–€70m incl €15m but limited to max 19.98% holding from MorphoSys AG 2019-10-08
Vivoryon–MC Services: public relations, 201910 service existent by MC Services 2019-10-08
vivoPharm–Protea Biosciences: investment, 201503–201601 acquisition $12m in cash + shares subject to raising necessary financing NOT REALISED 2015-03-31
1 2 3 ... 54 55 56  next pagenext page


Picture [LSE] – The Business Web Portal 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top